Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with diabetes
mellitus and increasing evidence suggests that patients with type 2 diabetes are at a …

Given the continued interest in defining the optimal management of individuals with type 2
diabetes, the Editor of Diabetes Care convened a working party of diabetes specialists to …

Obesity is a growing epidemic, and current medical therapies have proven inadequate.
Endogenous satiety hormones provide an attractive target for the development of drugs that …

Obesity, defined as the state of having excess body fat, is an epidemic and stillgrowing
health problem across the world. Data from the 2009–2010 National Health and Nutrition …

Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad
Española para el Estudio de la Obesidad de 2016 | Endocrinol. diabetes nutr. (Ed. impr.);64(supl.1) …

Aims To investigate the effects of a single dose of 1.2 mg liraglutide, a once‐daily glucagon‐
like peptide‐1 (GLP‐1) receptor agonist, on key renal variables in patients with type 2 …

Diabetes mellitus results from an interplay between insulin resistance and β-cell dysfunction.
Since their relative contributions to its pathogenesis are difficult to quantify, therapeutic …

Peptide hormones and proteins control body weight and glucose homeostasis by engaging
peripheral and central metabolic signalling pathways responsible for the maintenance of …

Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver
disease worldwide. Due to its association with obesity and diabetes and the fall in hepatitis …

The glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) exenatide, liraglutide and
lixisenatide have been shown to improve glycaemic control and beta‐cell function with a low …